Filip Lardon

List of Publications by Year
in descending order

137 papers	5,881 citations	76326 40 h-index	91884 69 g-index
137 all docs	137 docs citations	137 times ranked	9470 citing authors

#	Article	IF	Citations
1	Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFRâ€targeting agents to treat head and neck squamous cell carcinoma. Medicinal Research Reviews, 2022, 42, 112-155.	10.5	24
2	The CD70-CD27 axis in oncology: the new kids on the block. Journal of Experimental and Clinical Cancer Research, 2022, 41, 12.	8.6	53
3	Targeting hedgehog signaling in pancreatic ductal adenocarcinoma. , 2022, 236, 108107.		22
4	The effect of local <scp>nonâ€thermal</scp> plasma therapy on the <scp>cancerâ€immunity</scp> cycle in a melanoma mouse model. Bioengineering and Translational Medicine, 2022, 7, .	7.1	15
5	NTRK Gene Fusion Detection in a Pan-Cancer Setting Using the Idylla GeneFusion Assay. Journal of Molecular Diagnostics, 2022, 24, 750-759.	2.8	10
6	Characterization of acquired nutlin-3 resistant non-small cell lung cancer cells. , 2021, 4, 233-243.		6
7	Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. Cancers, 2021, 13, 987.	3.7	38
8	Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update. International Journal of Molecular Sciences, 2021, 22, 1807.	4.1	8
9	A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy. Journal of Experimental and Clinical Cancer Research, 2021, 40, 213.	8.6	42
10	The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy. Frontiers in Oncology, 2021, 11, 697967.	2.8	11
11	The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies. Frontiers in Immunology, 2021, 12, 737311.	4.8	28
12	Auranofin and Cold Atmospheric Plasma Synergize to Trigger Distinct Cell Death Mechanisms and Immunogenic Responses in Glioblastoma. Cells, 2021, 10, 2936.	4.1	35
13	The potential and controversy of targeting STAT family members in cancer. Seminars in Cancer Biology, 2020, 60, 41-56.	9.6	226
14	Specialized Blood Collection Tubes for Liquid Biopsy: Improving the Pre-analytical Conditions. Molecular Diagnosis and Therapy, 2020, 24, 113-124.	3.8	26
15	Novel combination immunotherapy for pancreatic cancer: potent antiâ€tumor effects with CD40 agonist and interleukinâ€15 treatment. Clinical and Translational Immunology, 2020, 9, e1165.	3.8	26
16	Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status. British Journal of Cancer, 2020, 123, 752-761.	6.4	25
17	Clinically Relevant Chemotherapeutics Have the Ability to Induce Immunogenic Cell Death in Non-Small Cell Lung Cancer. Cells, 2020, 9, 1474.	4.1	37
18	The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers, 2019, 11, 1093.	3.7	18

#	Article	IF	Citations
19	Multicenter Phase II Clinical Trial of Isolated Lung Perfusion in Patients With Lung Metastases. Annals of Thoracic Surgery, 2019, 108, 167-174.	1.3	17
20	Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells. Cancers, 2019, 11, 1597.	3.7	77
21	Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib. Cancers, 2019, 11, 98.	3.7	10
22	RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review. International Journal of Molecular Sciences, 2019, 20, 2183.	4.1	22
23	Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line. Biochemical Pharmacology, 2019, 166, 128-138.	4.4	12
24	InÂvitro study of the Poloâ€like kinase 1 inhibitor volasertib in nonâ€smallâ€cell lung cancer reveals a role for the tumor suppressor p53. Molecular Oncology, 2019, 13, 1196-1213.	4.6	17
25	Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation Protocol. Cancers, 2019, 11, 458.	3.7	73
26	Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status. Cancers, 2019, 11, 1893.	3.7	7
27	The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies. Molecules, 2019, 24, 4443.	3.8	2
28	RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment. Critical Reviews in Oncology/Hematology, 2019, 133, 85-91.	4.4	57
29	Unveiling a CD70-positive subset of cancer-associated fibroblasts marked by pro-migratory activity and thriving regulatory T cell accumulation. OncoImmunology, 2018, 7, e1440167.	4.6	33
30	Simultaneous targeting of <scp>EGFR</scp>,<scp> HER</scp>2, and <scp>HER</scp>4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines. Molecular Oncology, 2018, 12, 830-854.	4.6	36
31	Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade. OncoImmunology, 2018, 7, e1407899.	4.6	38
32	Monitoring EGFR TKI resistance in real time using ddPCR-based liquid biopsy: a case report. Journal of Clinical Pathology, 2018, 71, 754-756.	2.0	3
33	Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1Î± and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress. Cancers, 2018, 10, 126.	3.7	43
34	Deep sequencing of the TP53 gene reveals a potential risk allele for nonâ€"small cell lung cancer and supports the negative prognostic value of TP53 variants. Tumor Biology, 2017, 39, 101042831769432.	1.8	22
35	Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines. Cancer Biotherapy and Radiopharmaceuticals, 2017, 32, 229-238.	1.0	15
36	A Comparison of Cell-Free DNA Isolation Kits. Journal of Molecular Diagnostics, 2017, 19, 162-168.	2.8	164

#	Article	IF	Citations
37	MDM2 SNP309 and SNP285 Act as Negative Prognostic Markers for Non-small Cell Lung Cancer Adenocarcinoma Patients. Journal of Cancer, 2017, 8, 2154-2162.	2.5	4
38	Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and Hypoxia. Journal of Cancer, 2017, 8, 1441-1452.	2.5	11
39	Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells. Oncotarget, 2017, 8, 56968-56979.	1.8	59
40	Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy. Oncotarget, 2017, 8, 74058-74067.	1.8	9
41	Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines. Cancer Biotherapy and Radiopharmaceuticals, 2017, 32, 229-238.	1.0	8
42	Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor. Medicinal Research Reviews, 2016, 36, 749-786.	10.5	78
43	Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer. , 2016, 166, 71-83.		14
44	Efficacy Screening of Gloriosa Superba Extracts in a Murine Pancreatic Cancer Model Using ¹⁸F-FDG PET/CT for Monitoring Treatment Response. Cancer Biotherapy and Radiopharmaceuticals, 2016, 31, 99-109.	1.0	13
45	Primary skeletal muscle myoblasts from chronic heart failure patients exhibit loss of anti-inflammatory and proliferative activity. BMC Cardiovascular Disorders, 2016, 16, 107.	1.7	11
46	APR-246 (PRIMA-1 MET) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines. Cancer Letters, 2016, 375, 313-322.	7.2	51
47	TP53 and MDM2 genetic alterations in non-small cell lung cancer: Evaluating their prognostic and predictive value. Critical Reviews in Oncology/Hematology, 2016, 99, 63-73.	4.4	65
48	Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer. World Journal of Clinical Oncology, 2016, 7, 425.	2.3	7
49	Immune Checkpoint Modulation in Colorectal Cancer: Whatâ€™s New and What to Expect. Journal of Immunology Research, 2015, 2015, 1-16.	2.2	54
50	The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer. Oncotarget, 2015, 6, 22666-22679.	1.8	62
51	CD70: An emerging target in cancer immunotherapy. , 2015, 155, 1-10.		136
52	Decreased expression of ABAT and STC2 hallmarks ERâ€positive inflammatory breast cancer and endocrine therapy resistance in advanced disease. Molecular Oncology, 2015, 9, 1218-1233.	4.6	64
53	Phytochemical characterisation of a cytotoxic stem bark extract of Steganotaenia araliacea and identification of a protoflavanone by LCâ€“SPEâ€“NMR. Phytochemistry Letters, 2015, 12, 119-124.	1.2	11
54	In vitro and in vivo investigations on the antitumour activity of Chelidonium majus. Phytomedicine, 2015, 22, 1279-1287.	5.3	39

#	Article	IF	Citations
55	The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines. BMC Research Notes, 2015, 8, 203.	1.4	21
56	Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer. Oncotarget, 2015, 6, 13462-13475.	1.8	45
57	Abstract 3563: Unlocking the potential of CD70 as a therapeutic target in non-small cell lung cancer. , 2015, , .		0
58	Abstract 2593: Combination therapy with EGFR-TKI and cMET-TKIs in non-small cell lung cancer: the golden duo. , 2015, , .		0
59	Abstract 5584: Exhaled breath as diagnostic tool for malignant pleural mesothelioma. , 2015, , .		0
60	Abstract 3507: APR-246 reactivates mutant p53 in non-small cell lung cancer cell lines and sensitizes cells for CDDP treatment under normoxic and hypoxic conditions. , 2015, , .		0
61	Abstract 4328: New perspectives on the use of polo-like kinase 1 as a prognostic biomarker in non-small cell lung cancer. , 2015, , .		0
62	Establishment and characterization of cetuximab resistant head and neck squamous cell carcinoma cell lines: focus on the contribution of the AP-1 transcription factor. American Journal of Cancer Research, 2015, 5, 1921-38.	1.4	19
63	Pharmacological Levels of Withaferin A (Withania somnifera) Trigger Clinically Relevant Anticancer Effects Specific to Triple Negative Breast Cancer Cells. PLoS ONE, 2014, 9, e87850.	2.5	70
64	Contribution of ER and NF-ÎºB to endocrine resistance in inflammatory breast cancer. Breast Cancer Management, 2014, 3, 53-61.	0.2	1
65	Phase II Multicenter Clinical Trial of Pulmonary Metastasectomy and Isolated Lung Perfusion with Melphalan in Patients with Resectable Lung Metastases. Journal of Thoracic Oncology, 2014, 9, 1547-1553.	1.1	31
66	The radiosensitising effect of gemcitabine and its main metabolite dFdU under low oxygen conditions is in vitro not dependent on functional HIF-1 protein. BMC Cancer, 2014, 14, 594.	2.6	6
67	Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response. BMC Research Notes, 2014, 7, 337.	1.4	35
68	Overcoming cetuximab resistance in HNSCC: The role of AURKB and DUSP proteins. Cancer Letters, 2014, 354, 365-377.	7.2	53
69	Synthesis and in vivo preclinical evaluation of an 18F labeled uPA inhibitor as a potential PET imaging agent. Nuclear Medicine and Biology, 2014, 41, 477-487.	0.6	16
70	Expression profiling of migrated and invaded breast cancer cells predicts early metastatic relapse and reveals KrÃ¼ppel-like factor 9 as a potential suppressor of invasive growth in breast cancer. Oncoscience, 2014, 1, 69-81.	2.2	24
71	KrÃ¼ppel-like factors in cancer progression: three fingers on the steering wheel. Oncotarget, 2014, 5, 29-48.	1.8	58
72	Expression Analysis on Archival Material Revisited. Diagnostic Molecular Pathology, 2013, 22, 59-64.	2.1	26

#	Article	IF	Citations
73	Probiotics enhance the clearance of human papillomavirus-related cervical lesions. European Journal of Cancer Prevention, 2013, 22, 46-51.	1.3	93
74	Anti-Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance. Oncologist, 2013, 18, 850-864.	3.7	82
75	The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors. Current Pharmaceutical Design, 2013, 19, 907-917.	1.9	24
76	Abstract 99: Identification of genes involved in NFÎºB driven resistance to endocrine treatment in breast cancer.. , 2013, , .		1
77	Abstract 3910: Targeting urokinase plasminogen activator: evaluation of activity-based imaging probes in an orthotopic breast cancer model.. , 2013, , .		0
78	Abstract 5212: Preclinical study of the cytotoxic effect of nutlin-3a as monotherapy or in combination with gemcitabine in non-small cell lung cancer cell lines.. , 2013, , .		0
79	Abstract 5628: Overcoming cetuximab resistance in HNSCC: the role of AURKB and DUSP6.. , 2013, , .		0
80	Abstract P5-09-04: The effect of nuclear factor kappa B activation on cell proliferation of estrogen receptor positive breast cancer cell lines with different HER2-status. , 2013, , .		0
81	The intriguing interplay between therapies targeting the epidermal growth factor receptor, the hypoxic microenvironment and hypoxia-inducible factors. Current Pharmaceutical Design, 2013, 19, 907-17.	1.9	15
82	Selective pulmonary artery perfusion with melphalan is equal to isolated lung perfusion but superior to intravenous melphalan for the treatment of sarcoma lung metastases in a rodent model. European Journal of Cardio-thoracic Surgery, 2012, 42, 341-347.	1.4	12
83	The interaction between ER and NFÎºB in resistance to endocrine therapy. Breast Cancer Research, 2012, 14, 212.	5.0	89
84	Comparative Analysis of Dynamic Cell Viability, Migration and Invasion Assessments by Novel Real-Time Technology and Classic Endpoint Assays. PLoS ONE, 2012, 7, e46536.	2.5	229
85	The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors. Current Pharmaceutical Design, 2012, 19, 907-917.	1.9	3
86	Immune Cells in Colorectal Cancer: Prognostic Relevance and Role of MSI. Cancer Microenvironment, 2011, 4, 377-392.	3.1	90
87	Retention of the In Vitro Radiosensitizing Potential of Gemcitabine Under Anoxic Conditions, in p53 Wild-Type and p53-Deficient Nonâ€"Small-Cell Lung Carcinoma Cells. International Journal of Radiation Oncology Biology Physics, 2011, 80, 558-566.	0.8	10
88	The presence of Y chromosomal deoxyribonucleic acid in the female vaginal swab: Possible implications for human papillomavirus testing. Cancer Epidemiology, 2011, 35, 101-103.	1.9	10
89	Expression Analysis on Archival Material. Diagnostic Molecular Pathology, 2011, 20, 203-211.	2.1	16
90	Tumor Cells and Tumor-Associated Macrophages: Secreted Proteins as Potential Targets for Therapy. Clinical and Developmental Immunology, 2011, 2011, 1-12.	3.3	108

#	Article	IF	Citations
91	Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunology, 2010, 11, 19.	2.2	187
92	Detection of HPV and the role of p16INK4Aoverexpression as a surrogate marker for the presence of functional HPV oncoprotein E7 in colorectal cancer. BMC Cancer, 2010, 10, 117.	2.6	28
93	In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cells. BMC Cancer, 2010, 10, 441.	2.6	13
94	Everything you always wanted to know about HPV (but could not ask your doctor). Patient Education and Counseling, 2010, 81, 101-105.	2.2	30
95	KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis. British Journal of Cancer, 2010, 103, 1627-1636.	6.4	42
96	A Review of the Most Promising Biomarkers in Colorectal Cancer: One Step Closer to Targeted Therapy. Oncologist, 2010, 15, 699-731.	3.7	137
97	Counting clonogenic assays from normoxic and anoxic irradiation experiments manually or by using densitometric software. Physics in Medicine and Biology, 2010, 55, N167-N178.	3.0	16
98	Role of cell cycle perturbations in the combination therapy of chemotherapeutic agents and radiation. Future Oncology, 2010, 6, 1485-1496.	2.4	23
99	The role of apoptotic cell death in the radiosensitising effect of gemcitabine. British Journal of Cancer, 2009, 101, 628-636.	6.4	17
100	Feasibility of collecting self-sampled vaginal swabs by mail: quantity and quality of genomic DNA. European Journal of Clinical Microbiology and Infectious Diseases, 2009, 28, 1285-1289.	2.9	15
101	Chemoradiation interactions under reduced oxygen conditions: Cellular characteristics of an in vitro model. Cancer Letters, 2009, 286, 180-188.	7.2	19
102	Further mechanistic unravelling of the influence of the cell cycle effects on the radiosensitising mechanism of vinflunine, in vitro. Cancer Chemotherapy and Pharmacology, 2008, 62, 183-193.	2.3	3
103	Comparative study of the radiosensitising and cell cycle effects of vinflunine and vinorelbine, in vitro. BMC Cancer, 2008, 8, 65.	2.6	22
104	Detection of Microsatellite Instability in Colorectal Cancer Using an Alternative Multiplex Assay of Quasi-Monomorphic Mononucleotide Markers. Journal of Molecular Diagnostics, 2008, 10, 154-159.	2.8	40
105	Microsatellite instability in sporadic colon carcinomas has no independent prognostic value in a Belgian study population. European Journal of Cancer, 2008, 44, 2288-2295.	2.8	19
106	Review: Implications of In Vitro Research on the Effect of Radiotherapy and Chemotherapy Under Hypoxic Conditions. Oncologist, 2007, 12, 690-712.	3.7	124
107	Cell cycle effects of vinflunine, the most recent promising Vinca alkaloid, and its interaction with radiation, in vitro. Cancer Chemotherapy and Pharmacology, 2006, 58, 210-218.	2.3	22
108	The radiosensitising effect of difluorodeoxyuridine, a metabolite of gemcitabine, in vitro. Cancer Chemotherapy and Pharmacology, 2006, 58, 219-228.	2.3	24

#	Article	IF	Citations
109	The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines. BMC Cancer, 2006, 6, 142.	2.6	17
110	Comparison of three commonly used PCR-based techniques to analyze MSI status in sporadic colorectal cancer. Journal of Clinical Laboratory Analysis, 2006, 20, 52-61.	2.1	12
111	Combined Modality Therapy of Gemcitabine and Radiation. Oncologist, 2005, 10, 34-51.	3.7	134
112	Unraveling the Mechanism of Radiosensitization by Gemcitabine: The Role of TP53. Radiation Research, 2005, 164, 642-650.	1.5	27
113	Combined Pap and HPV testing in primary screening for cervical abnormalities: Should HPV detection be delayed until age 35?. European Journal of Cancer, 2005, 41, 2704-2708.	2.8	11
114	HPV in cervix and vagina. Sexually Transmitted Infections, 2004, 80, 249-250.	1.9	7
115	Concomitant Chlamydia trachomatis and human papilloma virus infection cannot be attributed solely to sexual behaviour. European Journal of Clinical Microbiology and Infectious Diseases, 2004, 23, 735-7.	2.9	12
116	Can cervical cancer screening be stopped at 50? The prevalence of HPV in elderly women. International Journal of Cancer, 2004, 108, 258-261.	5.1	39
117	The Prevalence of the Human Papillomavirus in Cervix and Vagina in Low-risk and High-risk Populations. Scandinavian Journal of Infectious Diseases, 2004, 36, 456-459.	1.5	13
118	Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies. Cancer Chemotherapy and Pharmacology, 2003, 51, 221-226.	2.3	121
119	Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro. International Journal of Radiation Oncology Biology Physics, 2003, 57, 1075-1083.	0.8	65
120	The radiosensitising effect of gemcitabine and the influence of the rescue agent amifostine in vitro. European Journal of Cancer, 2003, 39, 838-846.	2.8	24
121	In vitro interaction between Ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects. British Journal of Cancer, 2003, 89, 2305-2311.	6.4	37
122	Messenger RNA Electroporation of Human Monocytes, Followed by Rapid In Vitro Differentiation, Leads to Highly Stimulatory Antigen-Loaded Mature Dendritic Cells. Journal of Immunology, 2002, 169, 1669-1675.	0.8	56
123	mRNA-electroporated mature dendritic cells retain transgene expression, phenotypical properties and stimulatory capacity after cryopreservation. Leukemia, 2002, 16, 1324-1330.	7.2	53
124	Prevalence of Human Papillomavirus in Elderly Women with Cervical Cancer. Gynecologic and Obstetric Investigation, 2001, 52, 248-251.	1.6	10
125	Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood, 2001, 98, 49-56.	1.4	438
126	Human Papillomavirus Infection in the Female Population of Antwerp, Belgium: Prevalence in Healthy Women, Women With Premalignant Lesions and Cervical Cancer. Obstetrical and Gynecological Survey, 2001, 56, 696-697.	0.4	1

#	Article	IF	Citations
127	Specific checkpoints regulate plant cell cycle progression in response to oxidative stress. Plant Journal, 1999, 17, 647-656.	5.7	217
128	Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer. British Journal of Cancer, 1999, 79, 316-322.	6.4	138
129	Nonviral transfection of distinct types of human dendritic cells: high-efficiency gene transfer by electroporation into hematopoietic progenitor- but not monocyte-derived dendritic cells. Gene Therapy, 1998, 5, 700-707.	4.5	105
130	Effect of indomethacin on cell cycle dependent cyclic AMP fluxes in tobacco BY-2 cells. FEBS Letters, 1998, 422, 165-169.	2.8	73
131	Decrease in Nucleoside Diphosphate Kinase (NDPK/nm23) Expression during Hematopoietic Maturation. Journal of Biological Chemistry, 1998, 273, 13663-13668.	3.4	38
132	Generation of dendritic cells from bone marrow progenitors using GMâ€CSF, TNFâ€•α , and additional cytokines: antagonistic effects of ILâ€4 and IFNâ€•γ and selective involvement of TNFâ€• α receptorâ€1. Immunology, 1997, 91, 553-559.	4.4	89
133	Tumor necrosis factor alpha is a potent synergistic factor for the proliferation of primitive human hematopoietic progenitor cells and induces resistance to transforming growth factor beta but not to interferon gamma.. Journal of Experimental Medicine, 1996, 183, 705-710.	8.5	52
134	Interferon gamma selectively inhibits very primitive CD342+CD38- and not more mature CD34+CD38+ human hematopoietic progenitor cells.. Journal of Experimental Medicine, 1994, 180, 1177-1182.	8.5	67
135	Interferon-Î³ and interleukin-4 reciprocally regulate the production of monocytes/macrophages and neutrophils through a direct effect on committed monopotential bone marrow progenitor cells. European Journal of Immunology, 1993, 23, 1072-1077.	2.9	25
136	Direct effects of 13-cis and all-trans retinoic acid on normal bone marrow (BM) progenitors: Comparative study on BM mononuclear cells and on isolated CD 34+ BM cells. Annals of Hematology, 1993, 66, 61-66.	1.8	38
137	The effect of vanocomycin and teicoplanin on normal human bone marrow progenitor cells. Journal of Antimicrobial Chemotherapy, 1992, 30, 559-560.	3.0	0